🧬 ICD-10 CM I69.892 — Facial Weakness Following Other Cerebrovascular Disease
Billable Code Confirmed
ICD-10 CM I69.892 is a fully specified 6-character ICD-10-CM code valid for FY2026 inpatient facility and profee billing. The 6th character (2) designates facial weakness as the specific residual deficit type, distinguishing it from apraxia (0), dysphagia (1), ataxia (3), and other unspecified sequelae (8) within the I69.89x subcategory. This code is billable whenever documentation supports persistent facial weakness as a direct residual sequela of a prior qualifying cerebrovascular event classified under “other” cerebrovascular disease (I65-I67) — not ischemic infarction or intracranial hemorrhage.
Non-Billable Parent Codes
I69 (3 characters) — Sequelae of cerebrovascular disease — is the category header and non-billable; it requires the 4th character to identify the CVD etiology class and additional characters to specify the residual deficit, and submission will result in a claim edit. I69.8 (4 characters) — Sequelae of other cerebrovascular diseases — is non-billable and requires at minimum a 5th character designating the deficit category before any submission can be considered, and typically the full 6th character is also required. I69.89 (5 characters) — Other sequelae of other cerebrovascular diseases — is non-billable without the 6th character specifying the deficit type; submitting this truncated code will be rejected by both facility and profee claim edits in all standard payer systems.
Clinical Context
The phrase “other cerebrovascular disease” in I69.892 refers specifically to conditions classified in categories I65-I67 — including moyamoya disease, cerebral arteritis, cerebral venous sinus thrombosis, and progressive vascular leukoencephalopathy — as opposed to cerebral infarction (I63.x) or intracranial hemorrhage (I60-I62). Facial weakness in this context reflects an upper motor neuron (UMN) pattern due to corticobulbar tract disruption, which must be clinically distinguished from lower motor neuron facial palsy such as Bell’s palsy (G51.0) before code assignment. When documentation uses non-specific language like “facial droop” or “facial asymmetry” in a patient with a complex CVD history, a physician query is required to confirm etiology before selecting I69.892 over another code in the I69.x92 family or over a peripheral nerve code.
Code Classification
ICD-10 CM I69.892 is an ICD-10-CM diagnosis code — not a procedure code — representing a residual neurological deficit of a prior cerebrovascular event and usable as either principal or secondary diagnosis depending on the encounter reason. It must never be assigned for an active, acute, or evolving cerebrovascular event; acute facial involvement during TIA or stroke should be coded from the I60-I67 range with appropriate manifestation codes during that encounter. Once the acute phase has resolved and only the sequela remains, I69.892 replaces the acute CVD diagnosis for subsequent encounter coding per Official Guideline I.C.9.d.^1^
🔍 Code Description
Facial weakness following other cerebrovascular disease (I69.892) identifies a persistent reduction in voluntary facial muscle function that remains as a residual sequela after a qualifying cerebrovascular event classified under “other” cerebrovascular diseases (I65-I67) — specifically excluding cerebral infarction and intracranial hemorrhage, which have their own parallel sequela codes. The neurological substrate of this deficit is typically an upper motor neuron lesion involving the corticobulbar tract, the pathway connecting the contralateral motor cortex to the facial nerve nucleus in the lower pons, resulting in contralateral lower facial paresis with characteristic forehead sparing due to bilateral hemispheric representation of frontalis motor function. Unlike G51.0 (Bell’s palsy), which involves direct damage to cranial nerve VII at the peripheral level, I69.892 captures central nervous system-origin facial weakness where the facial nerve itself is structurally intact but deprived of supranuclear motor input.^6^
Qualifying underlying conditions for this code include I67.5 (moyamoya disease), I67.7 (cerebral arteritis NEC), I67.3 (progressive vascular leukoencephalopathy), hypertensive encephalopathy, and cerebral venous sinus thrombosis, all of which can produce focal cortical or subcortical lesions with residual facial motor deficits depending on lesion location and extent. In the inpatient profee setting, I69.892 is encountered across neurology, otolaryngology (for formal facial nerve evaluation), and PM&R (during inpatient rehabilitation for functional motor retraining), making cross-specialty familiarity with this code essential for accurate claim submission. Per ICD-10-CM Official Guidelines, sequela codes may be used at any point after the acute phase — there is no time restriction — and I69.892 may appear for the first time years after the original cerebrovascular event if the deficit is clinically relevant to the current encounter.^1^
🌳 Code Tree / Hierarchy
I69 — Sequelae of cerebrovascular disease ❌ Non-billable
│
├── I69.3 — Sequelae of cerebral infarction ❌ Non-billable
│ └── I69.392 — Facial weakness following cerebral infarction ✅ Billable
│
├── I69.8 — Sequelae of other cerebrovascular diseases ❌ Non-billable
│ │
│ ├── I69.80 — Unspecified sequelae of other CVD ✅ Billable
│ ├── I69.85 — Hemiplegia/hemiparesis following other CVD ❌ Non-billable
│ │ ├── I69.851 — Right dominant side ✅ Billable
│ │ └── I69.852 — Left dominant side ✅ Billable
│ │
│ └── I69.89 — Other sequelae of other cerebrovascular diseases ❌ Non-billable
│ ├── I69.890 — Apraxia following other CVD ✅ Billable
│ ├── I69.891 — Dysphagia following other CVD ✅ Billable
│ ├── I69.892 — Facial weakness following other CVD ◀ THIS CODE ✅ Billable
│ ├── I69.893 — Ataxia following other CVD ✅ Billable
│ └── I69.898 — Other sequelae of other CVD ✅ Billable
│
└── I69.9 — Sequelae of unspecified cerebrovascular diseases ❌ Non-billable
Why the " Other" Etiology Designation Is a Coding Decision Point
Using I69.892 when the underlying event was actually a cerebral infarction is a specificity error — the correct code in that case is I69.392. Payers increasingly cross-reference documented history against sequela code etiology designation, and mismatched classification can trigger medical necessity denials or RAC audit flags, particularly under Medicare and Medicare Advantage plans that validate longitudinal diagnostic coding consistency.
Tip
When a patient presents for rehab or neurology follow-up with documented residual facial weakness and a history of moyamoya disease, cerebral venous thrombosis, or cerebral arteritis — but NOT stroke or hemorrhage — I69.892 is the correct sequela code. If the residual deficit follows ischemic stroke, use I69.392; if it follows subarachnoid hemorrhage, use I69.092; if it follows intracerebral hemorrhage, use I69.192.
✅ Includes
ICD-10 CM I69.892 includes any residual facial paresis or droop that is the direct consequence of a prior cerebrovascular event classified under other cerebrovascular diseases (I65-I67), applied only after the original event has passed and the facial weakness persists as a long-term sequela. The code applies regardless of elapsed time since the qualifying event, as ICD-10-CM sequela coding has no statutory time restriction and the deficit may be newly documented on any subsequent encounter where it is clinically relevant.^2^ Facial weakness captured here may range in severity from subtle lower facial asymmetry detectable only on close examination to complete unilateral facial motor paralysis with sialorrhea and significant functional impairment. Documentation by the treating provider characterizing the facial finding as a “residual effect,” “sequela,” or “late effect” of the prior cerebrovascular condition is required to support code selection at this specificity.
❌ Excludes
Excludes 1
ICD-10 CM G51.0 — Bell’s palsy is mutually exclusive with I69.892 because Bell’s palsy is idiopathic lower motor neuron facial nerve palsy — an entirely different mechanism from the central vascular etiology captured by I69.892 — and coding both simultaneously implies contradictory etiologies for the same finding. If the facial weakness is confirmed to be the result of a prior cerebrovascular event, G51.0 must not be assigned, and if a concurrent new-onset peripheral facial nerve event is documented as separate and distinct, the clinical encounter must clearly support that separation. G46.3 — Brain stem stroke syndrome is an acute manifestation code used during the initial event encounter; it is not a sequela code, and when only the residual facial weakness remains after resolution of the acute phase, I69.892 replaces G46.3 for all subsequent coding encounters.
Danger
The most frequent Excludes 1 error with I69.892 is assigning G51.0 when a patient with a known CVD history presents with facial weakness — particularly in OTO consultations where Bell’s palsy is a primary differential. The provider must document whether the etiology is central-vascular (supporting I69.892) or peripheral-idiopathic (supporting G51.0) before any code is assigned; a CDI query is appropriate when the medical record does not make this distinction explicit.
Excludes 2
ICD-10 CM I69.392 — Facial weakness following cerebral infarction may be coded separately from I69.892 in the rare scenario where a patient has independent facial weakness sequelae attributable to two distinct prior cerebrovascular events of different etiologies — but documentation must clearly delineate that each instance of facial weakness arose from a different, separately identified historical event. G51.9 — Disorder of facial nerve, unspecified may be coded in addition to I69.892 when a concurrent peripheral facial nerve disorder of a clinically distinct and separately documented etiology is present in the same encounter.
📋 Clinical Overview
UMN vs LMN Facial Weakness — The Essential Coding and CDI Distinction
Facial weakness following cerebrovascular disease is mechanistically an upper motor neuron deficit arising from supranuclear damage to the corticobulbar tract, and distinguishing this from lower motor neuron facial palsy is both a clinical imperative and a coding accuracy requirement. Coders in OTO and PM&R settings must recognize the physical examination features documented in the record that support each designation, and should query when those features are absent or ambiguous in the documentation. The differential between I69.892 and a peripheral facial nerve code has direct implications for DRG grouping, MDC assignment, and downstream payer review.
| Feature | I69.892 | I69.392 | G51.0 |
|---|---|---|---|
| Etiology | Sequela of other CVD (I65-I67): arteritis, moyamoya, venous thrombosis | Sequela of cerebral infarction (ischemic stroke, I63.x) | Idiopathic peripheral facial nerve palsy; no CVD required |
| Neuron Type | Upper motor neuron (UMN); corticobulbar tract lesion | Upper motor neuron (UMN); corticobulbar tract lesion | Lower motor neuron (LMN); CN VII direct involvement |
| Forehead Involvement | Forehead typically spared — bilateral hemispheric innervation of frontalis | Forehead typically spared — same UMN mechanism | Forehead involved — entire ipsilateral face affected including brow |
| MDC / DRG Grouping | MDC 01 → DRG 056/057 | MDC 01 → DRG 056/057 or stroke-specific DRG | MDC 03 (Ear, Nose, Mouth & Throat) → separate DRG tier |
| HCC Impact | N/A — not directly HCC-mapped | N/A — not directly HCC-mapped | N/A — not HCC-mapped |
Important
A CDI query opportunity exists whenever the medical record documents “facial droop” or “facial asymmetry” in a patient with a history of cerebrovascular disease without specifying whether the finding is a residual sequela of that prior event or a new neurological development. In OTO inpatient consultations specifically, the consulting physician’s note should distinguish UMN from LMN pattern; if it does not, query before assigning I69.892 vs G51.0 or G51.9.
Manifestations & Symptom Burden
Contralateral lower facial paresis — the hallmark UMN pattern; the nasolabial fold flattens and the mouth corner droops on the side contralateral to the intracranial lesion, with the forehead remaining symmetric bilaterally. Dysarthria — slurred or slowed speech often accompanies facial weakness due to impaired orbicularis oris and perioral muscle function; if documented, code additionally with I69.822 (dysarthria following other cerebrovascular disease). Dysphagia — oral-phase dysphagia may co-occur when lip closure and bolus control are impaired by facial motor weakness; if documented separately, assign I69.891 in addition to I69.892. Sialorrhea and drooling — a functional consequence of incomplete lip competence; if the provider documents this finding as clinically significant, a CDI query to capture it separately may be warranted. Psychosocial impact — facial asymmetry can contribute to depression, social withdrawal, and reduced quality of life in rehabilitation patients; any documented mood disorder should be separately coded as an additional diagnosis.
Tip
When dysphagia (I69.891) and facial weakness (I69.892) are both present as documented residual deficits from the same cerebrovascular event, both may and should be coded per ICD-10-CM guidelines — each represents a distinct, separately identifiable clinical sequela. Capturing all individual deficit codes provides a more accurate comorbidity profile, supports medical necessity for rehabilitation services, and maximizes legitimate secondary diagnosis capture.
💰 HCC Risk Adjustment
| Field | Detail |
|---|---|
| HCC Category | N/A — Not HCC-Mapped (CMS HCC Model v28) |
| RAF Weight | None assigned for I69.892 in isolation |
| Model Version | CMS HCC Model v28 (effective 2024 plan year onward) |
| Annual Capture Requirement | Not applicable — code does not independently contribute to RAF |
| Related HCC-Mapped Sequelae | I69.851-I69.852 → HCC 103/104 (Hemiplegia/Hemiparesis); I69.891 — verify current v28 mapping |
ICD-10 CM I69.892 does not carry a direct HCC mapping in CMS Model v28, meaning it does not increase the RAF score for Medicare Advantage patients when coded in isolation. However, if co-existing sequelae are present — particularly I69.851 or I69.852 (hemiplegia, HCC 103/104) — those codes must be captured annually on each qualifying encounter to preserve RAF credit, and I69.892 supports the broader clinical picture establishing the severity and permanence of the CVD sequelae burden. For Wisconsin Medicaid, BCBS of WI, UMR, UHC, and Aetna encounters, even non-HCC-mapped codes such as I69.892 contribute to utilization management decisions and may be required by payer policy to authorize ongoing rehabilitation or skilled nursing services. Thorough sequela documentation and coding remain a compliance and reimbursement integrity priority regardless of HCC status.^3^
🏥 MS-DRG Assignment
| Scenario | DRG | Title | Weight (Approx.) |
|---|---|---|---|
| I69.892 as PDX + MCC present | 056 | Degenerative Nervous System Disorders with MCC | ~2.5 |
| I69.892 as PDX + CC or no CC/MCC | 057 | Degenerative Nervous System Disorders without MCC | ~1.3 |
| IRF admission; sequela as secondary Dx | 945 | Rehabilitation with CC or MCC | ~1.7 |
| IRF admission; no CC/MCC present | 946 | Rehabilitation without CC/MCC | ~0.9 |
When I69.892 serves as the PDX for an acute inpatient encounter, it groups to MDC 01 under the DRG 056/057 split, with the presence of an MCC among secondary diagnoses (such as sepsis, respiratory failure, or major acute comorbidity) required to achieve the higher-weighted DRG 056. I69.892 itself is not designated as a CC or MCC in the MS-DRG v43 (FY2026) grouper and therefore does not independently upgrade the DRG assignment for encounters where it appears as a secondary diagnosis. In inpatient rehabilitation facility (IRF) encounters, the PDX is typically the functional deficit driving the admission, with I69.892 contributing to the secondary diagnosis burden and supporting medical necessity documentation. Coders should evaluate whether the original underlying cerebrovascular disease — moyamoya (I67.5), arteritis (I67.7), or other I65-I67 conditions — is still active and documented, as those codes may carry independent CC/MCC weight that affects DRG assignment. Verify all relative weights against the published CMS MS-DRG v43 Final Rule, as annual revisions may change weight values.^4^
🔗 Related ICD-10-CM Codes
Facial Weakness Sequelae — Full Etiology Family
- I69.092 — Facial weakness following nontraumatic subarachnoid hemorrhage
- I69.192 — Facial weakness following nontraumatic intracerebral hemorrhage
- I69.292 — Facial weakness following other and unspecified intracranial hemorrhage
- I69.392 — Facial weakness following cerebral infarction
- I69.892 — Facial weakness following other cerebrovascular disease (this code)
Commonly Co-Coded Sequelae and Related Neurological Codes
- I69.822 — Dysarthria following other cerebrovascular disease (frequent co-sequela)
- I69.891 — Dysphagia following other cerebrovascular disease (frequent co-sequela)
- I69.851 — Hemiplegia and hemiparesis following other CVD, right dominant side
- I67.5 — Moyamoya disease (common underlying “other CVD” etiology)
- I67.7 — Cerebral arteritis, NEC (alternate underlying etiology)
- G51.0 — Bell’s palsy (key differential; peripheral LMN palsy; Excludes 1)
- G51.9 — Disorder of facial nerve, unspecified (Excludes 2; may co-exist if separately documented)
🛠️ Commonly Associated CPT Codes
- 92516 — Facial nerve function studies: Used when a neurologist, otolaryngologist, or physiatrist performs formal assessment of facial nerve motor function including electromyographic evaluation of facial musculature; in the inpatient profee setting modifier -26 (professional component) applies when testing is performed using facility equipment, and documentation must specify the clinical indication and muscles tested.
- 95885 — Needle electromyography, limited, with nerve conduction studies: When EMG of facial musculature is performed as part of a broader neuromuscular evaluation characterizing the distribution and severity of facial motor deficit, this CPT may apply; documentation must identify each muscle studied, the number of extremities, and the clinical rationale distinguishing limited from complete study.
- 97110 — Therapeutic procedure, one or more areas, each 15 minutes; therapeutic exercises: Used by physical or occupational therapists in inpatient rehabilitation when facial neuromuscular retraining exercises are formally documented in the plan of care; must be billed in 15-minute units with documented skilled need.
- 97530 — Therapeutic activities, direct, one-on-one patient contact: Applicable in PM&R when structured functional activities targeting oral motor coordination and facial motor retraining are documented as distinct from therapeutic exercise; requires documentation of skilled therapeutic intent and separate activity from units billed under 97110.
- 92507 — Treatment of speech, language, voice, communication, and/or auditory processing disorder; individual: SLP services targeting dysarthria or oral-phase dysphagia co-occurring with I69.892; particularly relevant in inpatient rehabilitation where speech pathology is part of the interdisciplinary team and documentation captures specific treatment modalities and measurable functional goals.
NCCI Bundling Considerations
92516 (facial nerve function studies) may bundle with broader electrophysiologic studies when performed on the same date by the same provider — coders must verify that facial nerve function testing is not already captured within the work of a concurrently billed EMG or nerve conduction study code before billing both. 97110 and 97530 are time-based codes subject to NCCI edits when billed for overlapping treatment time units by the same therapist on the same date; each code must represent distinctly documented skilled therapeutic activity with separate timed documentation.^5^
🔬 ICD-10-PCS Crosswalk
- F07L0ZZ — Motor Treatment, Face Muscles, None: Used when a physical or occupational therapist provides therapeutic exercise specifically targeting facial motor function in an inpatient rehabilitation setting; Section F (Physical Rehabilitation), Type 7 (Motor Treatment), Body Part L (Face Muscles); verify the exact body part and qualifier characters against FY2026 ICD-10-PCS tables, as PCS updates may affect character assignments annually.
- F01Z0ZZ — Motor and/or Nerve Function Assessment, Neurological System: Applicable when a comprehensive functional assessment documents the neurological deficit including facial weakness as part of the inpatient rehabilitation admission evaluation; supports medical necessity establishment for IRF-level care.
- F09Z0ZZ — Communication Treatment: When speech-language pathology provides motor speech or communication treatment addressing dysarthria or functional communication deficits co-occurring with I69.892’s facial motor weakness, this Section F root type captures the therapeutic service in the PCS record.
- F07Z0ZZ — Motor Treatment, Whole Body, None: Assigned when the inpatient rehabilitation motor treatment program addresses global motor deficits including but not limited to facial weakness as part of an integrated, non-isolated treatment plan; facility coding teams should validate character specificity against the PCS FY2026 Tabular.
💊 Coding Scenarios and Examples
Scenario 1 — Inpatient Rehabilitation, Facial Weakness and Dysphagia Post-Moyamoya
A 47-year-old female with a documented history of I67.5 (moyamoya disease) is admitted to an inpatient rehabilitation facility for intensive interdisciplinary therapy following a moyamoya-related ischemic event six months prior. She presents with persistent right-sided lower facial droop, oral-phase dysphagia requiring modified texture diet, and mild dysarthria; the interdisciplinary team documents all three deficits as sequelae of the prior cerebrovascular event. Rehabilitation goals include oral motor retraining, structured swallowing therapy, and therapeutic exercise for facial motor function.
Correct Coding:
- PDX: Appropriate rehabilitation encounter or functional deficit code per facility sequencing policy
- I67.5 — Moyamoya disease (underlying active condition)
- I69.892 — Facial weakness following other cerebrovascular disease
- I69.891 — Dysphagia following other cerebrovascular disease
- I69.822 — Dysarthria following other cerebrovascular disease
Sequencing: The PDX should reflect the primary reason for the inpatient rehabilitation admission per facility policy and payer requirements; the three sequela codes (I69.892, I69.891, I69.822) are additional diagnoses establishing the functional deficit burden driving rehabilitation level of care. The underlying I67.5 is listed as an additional diagnosis providing clinical context for the etiology.
CDI Note: If documentation states “facial droop” or “swallowing difficulty” without explicitly linking these findings to the moyamoya history, a physician query is required before assigning I69.892 and I69.891; the causal relationship must be provider-documented to support sequela code assignment.
Scenario 2 — Acute Neurology Admission, Evaluation of Facial Weakness in Cerebral Arteritis Patient
A 63-year-old male with a known history of cerebral arteritis (I67.7) is admitted for evaluation of new-onset facial asymmetry noted over the prior week. Neuroimaging excludes new ischemic infarction or hemorrhage. The admitting neurologist documents “left-sided lower facial weakness with forehead sparing, consistent with UMN pattern; most consistent with residual sequela of prior cerebral arteritis-related vascular injury; no evidence of acute event.”
Correct Coding:
- PDX: I69.892 — Facial weakness following other cerebrovascular disease (the clinical reason for admission is evaluation and management of this sequela)
- I67.7 — Cerebral arteritis, NEC (underlying etiology, active and documented)
Sequencing: I69.892 is the PDX as the documented reason for the inpatient encounter; the arteritis code (I67.7) provides the etiologic context as an additional diagnosis. If a new acute arteritis flare were documented, sequencing would require reassessment with the neurologist.
CDI Note: If the physician documents “facial palsy — etiology uncertain” rather than definitively attributing it to the prior arteritis history, a query is appropriate before assigning I69.892 vs G51.0 or G51.9.
Scenario 3 — OTO Inpatient Consultation, Facial Nerve Evaluation
A hospitalized 71-year-old patient with a history of cerebral venous sinus thrombosis presents with residual left-sided facial weakness. OTO is consulted to evaluate for concurrent Bell’s palsy vs central etiology. The consulting otolaryngologist documents: “Facial weakness left lower face with forehead sparing, UMN pattern, no evidence of peripheral CN VII involvement; consistent with prior cerebrovascular event, not Bell’s palsy. Facial nerve function study ordered.”
Correct Coding (Profee Consultation):
- I69.892 — Facial weakness following other cerebrovascular disease (primary diagnosis for the consult)
- CPT: 92516 — Facial nerve function studies (with modifier -26, professional component)
- CPT: Appropriate subsequent inpatient E/M code for the consultation visit
Sequencing: I69.892 drives the profee claim as the primary reason for the OTO consultation; 92516 with -26 captures the diagnostic study. The OTO documentation explicitly ruling out Bell’s palsy (G51.0) is critical supporting evidence for the I69.892 selection and should be present in the record before claim submission.
CDI Note: OTO consultation notes should clearly state that the facial weakness is UMN in origin and attributable to the prior cerebrovascular event — vague language such as “facial palsy” without mechanism or origin specified creates a coding documentation gap that a concurrent CDI review should flag.
⚠️ Coding Pitfalls and Tips
Pitfall 1 — Assigning G51.0 Instead of I69.892: The most common error is defaulting to Bell’s palsy when a patient with a CVD history presents with facial weakness; Bell’s palsy is a peripheral, idiopathic LMN palsy and is mutually exclusive with I69.892 — the documentation must specify UMN etiology and CVD causation before I69.892 can be assigned, and a CDI query is appropriate if it does not.
Pitfall 2 — Wrong Sequela Etiology Code Selection: I69.892 applies only when the qualifying event falls under other cerebrovascular diseases (I65-I67); if the underlying event was a cerebral infarction, use I69.392, and if it was intracerebral hemorrhage, use I69.192 — mismatched etiology-sequela pairing is increasingly flagged in payer cross-validation logic and can trigger claim denial or audit.
Pitfall 3 — Submitting Non-Billable Parent Code I69.89: Submitting I69.89 without the mandatory 6th character (2) will trigger a claim-level edit across all payer systems; always verify that the full 6-character code I69.892 is present on the claim before submission.
Pitfall 4 — Omitting Co-Occurring Sequelae: When I69.891 (dysphagia) and I69.822 (dysarthria) are also present and documented, all separately identified sequelae must be individually coded — omitting them understates the comorbidity and functional burden, reduces medical necessity support for rehabilitation services, and may miss CC/MCC capture if associated secondary diagnoses qualify.
Pitfall 5 — Failing to Query the Causal Relationship: Vague documentation such as “facial droop” or “facial asymmetry” in a patient with a CVD history does not independently establish sequela status; the provider must document that the facial weakness is attributable to the prior cerebrovascular event, and a CDI query should be generated when this causal link is absent or implicit rather than explicit.
Tip — No Time Limit on Sequela Coding: Per ICD-10-CM Official Guidelines, sequela codes under the I69.xxx family may be assigned at any point following the acute phase — there is no mandatory elapsed time, and I69.892 may be assigned for the first time on an encounter occurring years after the original qualifying cerebrovascular event, provided clinical documentation supports the residual deficit as ongoing and relevant to the current encounter.^1^